Clayton has been with Freeman Technology since 2008 in a role that has encompassed both sales and applications support. As operations manager he will be responsible for all the day-to-day activities of the company, including overall management of the administration, production, r&d, sales and customer support teams.
In expanding the management team Tim Freeman, director of operations, anticipates further growth and greater opportunity to contribute expertise to the powder processing industries.
‘We want to deliver the best possible technical and applications support to our customers at all times and part of Jamie’s new role will be to ensure that every aspect of our operation runs efficiently,’ he said.
Freeman Technology appoints operations manager
Jamie Clayton takes responsibility for day-to-day activities
You may also like
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory
FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus
AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Analysis
Introducing Shimadzu’s MultiNA II: Redefining precision in life science analysis
Designed with users in mind, the MultiNA II MCE-301 is a fully automated microchip electrophoresis system designed to accelerate and simplify genetic analysis workflows in pharmaceutical and biopharmaceutical laboratories
Manufacturing
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform
The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods